NCT05930899 Translational-Omics in Aortic Stenosis (TOmAS) Biobank
| NCT ID | NCT05930899 |
| Status | Recruiting |
| Phase | — |
| Sponsor | McGill University Health Centre/Research Institute of the McGill University Health Centre |
| Condition | Cardiovascular Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2017-10-12 |
| Primary Completion | 2040-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2017-10-12 with a primary completion date of 2040-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of the TOmAS Biobank is the conservation of biological material (plasma, saliva, and tissue explanted during surgery), genetic material (DNA, RNA, etc.), and clinical data ("material/data") collected from patients with cardiovascular diseases (CVD) as well as from control participants, in order to allow future studies evaluating novel proteomic, transcriptomic and epigenomic markers (as well as other emerging -omic technologies) for CVD (i.e. aortic stenosis, cardiomyopathy, myorcardial infarction, etc). The study of physiological and genetic factors will allow for the discovery of new genomic and other -omic (including proteomic, transcriptomic and epigenomic) biomarkers associated with CVD which will lead to an improved understanding of the underlying biology of CVD and may provide future insights into the prevention and treatment of this type of disease.
Eligibility Criteria
Inclusion Criteria: * CVD diagnosis including, but not limited to: Aortic Stenosis, Coronary Heart Disease, Heart Failure, Atrial Fibrilation, Dilated Cardiomyopathy, Myocardial Infarction, and Spontaneous Coronary Artery Dissection. * Undergoing cardiac surgery for non-aortic valve pathology Exclusion Criteria: * Individuals with Congenital heart disease will be excluded
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05930899 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Cardiovascular Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05930899 currently recruiting?
Yes, NCT05930899 is actively recruiting participants. Contact the research team at george.thanassoulis@mcgill.ca for enrollment information.
Where is the NCT05930899 trial being conducted?
This trial is being conducted at Montreal, Canada, Montreal, Canada.
Who is sponsoring the NCT05930899 clinical trial?
NCT05930899 is sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. The trial plans to enroll 10,000 participants.